Participants reported improvement in their overall health-related quality of life
The drug belongs to the family of incretin glucagon-like peptide-1 (GLP-1) receptor agonists that have been used in type 2 diabetes treatment for almost 20 years
Semaglutide was
We assessed the efficacy, safety, and tolerability of semaglutide monotherapy, compared with placebo, in treatment-naive patients with type 2 diabetes who had insufficient glycaemic control with diet and exercise alone
Of the total drug interactions, 2 are major, 247 are moderate, and 1 is minor
For Type 2 diabetes, Rybelsus (semaglutide) is an oral Ozempic alternative that contains the same active ingredient
Rybelsus can be
Whereas earlier work had hypothesized that GLP-1 therapy might lead to improved exacerbation frequency and
Semaglutide is selective glucagon-like peptide-1 (GLP-1) receptor agonist
IgE-mediated reactions have been reported in other GLP-1 agonists, however none have been reported with semaglutide